TCIM
ATRA icon

TIAA CREF Investment Management’s Atara Biotherapeutics ATRA Stock Holding History

TIAA CREF Investment Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$3.57M Buy
3,591
+365
+11% +$339K ﹤0.01% 1655
2018
Q4 		$2.8M Sell
3,226
-65
-2% -$60.4K ﹤0.01% 1750
2018
Q3 		$3.4M Sell
3,291
-284
-8% -$278K ﹤0.01% 1838
2018
Q2 		$3.29M Buy
3,575
+622
+21% +$668K ﹤0.01% 1895
2018
Q1 		$2.88M Buy
2,953
+474
+19% +$432K ﹤0.01% 1901
2017
Q4 		$1.12M Sell
2,479
-73
-3% -$27K ﹤0.01% 2411
2017
Q3 		$1.06M Sell
2,552
-164
-6% -$61.8K ﹤0.01% 2488
2017
Q2 		$950K Buy
2,716
+187
+7% +$72K ﹤0.01% 2573
2017
Q1 		$1.3M Sell
2,529
-198
-7% -$82K ﹤0.01% 2388
2016
Q4 		$968K Sell
2,727
-48
-2% -$20.3K ﹤0.01% 2558
2016
Q3 		$1.48M Sell
2,775
-90
-3% -$48.9K ﹤0.01% 2339
2016
Q2 		$1.61M Buy
2,865
+787
+38% +$378K ﹤0.01% 2255
2016
Q1 		$989K Sell
2,078
-873
-30% -$393K ﹤0.01% 2478
2015
Q4 		$1.95M Sell
2,951
-59
-2% -$44.6K ﹤0.01% 2173
2015
Q3 		$2.37M Buy
3,010
+400
+15% +$488K ﹤0.01% 2042
2015
Q2 		$3.44M Buy
2,610
+1,845
+241% +$2.12M ﹤0.01% 1946
2015
Q1 		$795K Buy
765
+650
+565% +$430K ﹤0.01% 2741
2014
Q4 		$77K Buy
+115
New +$70.2K ﹤0.01% 3125

Other funds holding ATRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TIAA CREF Investment Management's ATRA Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Atara Biotherapeutics (ATRA) stake by 11% in Q1 2019, buying an estimated $339K and bringing the position to 3,591 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

TIAA CREF Investment Management first reported a position in ATRA in Q4 2014 and has held it in 18 quarters since. 120 funds tracked by Wall St. Rank hold ATRA as of Q1 2019.

  • TIAA CREF Investment Management held 3,591 shares of Atara Biotherapeutics worth $3.57M as of Q1 2019.
  • TIAA CREF Investment Management bought 365 Atara Biotherapeutics shares in Q1 2019, an estimated $339K.
  • Atara Biotherapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1655 holding.
  • TIAA CREF Investment Management first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 18 quarters since.
  • 120 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.